Delivery Order SPE2DB22D3301-SPE2DB25FY8DW
- Not listed
- The Defense Logistics Agency awarded a $11,087.70 delivery order to AmerisourceBergen Drug Corp for the supply of Padcev 20 mg vials, with performance to be completed by September 23, 2025. This competitively awarded, firm fixed-price contract is being executed from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $5,543.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for 30 mg vials of Padcev on August 8, 2025, with an ultimate completion date of August 29, 2025. This competitive award, with no set-aside designation, is being performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with the agency. This award is...
- The Defense Logistics Agency awarded a $14,783.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for 20 mg vials of Padcev, a specialized oncology medication. The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), is scheduled for completion by October 6, 2025. The pharmaceutical will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, and no...
- The Defense Logistics Agency awarded a delivery order valued at $11,087.60 to AmerisourceBergen Drug Corp for the supply of Padcev 30 mg vials. This competitively awarded, firm fixed price contract was executed on September 2, 2025, with an ultimate completion date of September 23, 2025. The pharmaceutical distributor will perform the delivery at its corporate office location in Conshohocken, Pennsylvania. As a non-set-aside procurement, this award reflects AmerisourceBergen's continued...
- The Defense Logistics Agency awarded a delivery order valued at $11,087.70 to AmerisourceBergen Drug Corp for the supply of Padcev 20 mg vials. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 19, 2025, and carries no set-aside designation. The contract will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award on September 15, 2025, for Padcev 30 mg vials with a ceiling value of $83,157.00. This firm fixed price contract, issued by the Defense Logistics Agency's Medical Supply Chain, represents a competitively awarded procurement with no set-aside designation and is scheduled for completion by October 6, 2025. The contract is structured as a child delivery...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of PADCEV 30 mg vials, a specialized pharmaceutical product. This firm fixed-price delivery order carries a ceiling value of $27.7K and is scheduled for completion by August 4, 2025. The contract was awarded competitively with no set-aside designation, and performance will occur at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for PADCEV 20 mg vials valued at $7,391.80 on August 19, 2025, with completion targeted for September 10, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $8,315.70 to AmerisourceBergen Drug Corp for PADCEV 30 mg vials, a pharmaceutical product used in cancer treatment. The contract, issued on August 25, 2025, with an ultimate completion date of September 16, 2025, carries firm fixed pricing under a non-competitive, non-set-aside delivery order arrangement. Performance will occur at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $27,719 on July 28, 2025, for the supply of Padcev 30 mg vials. This firm fixed-price delivery order, which is expected to be completed by August 18, 2025, was issued without a set-aside designation, indicating it was competitively awarded. The contract is performed at the awardee's Corporate Office location in Conshohocken, PA and is funded...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY8DWDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $7,391.80 delivery order for Padcev 20 mg vials under a firm fixed-price contract with an ultimate completion date of August 11, 2025. This is a non-set-aside award, meaning it was competitively awarded without restrictions. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply pharmaceutical products and medical supplies globally to support military healthcare programs, including customers such as the Defense Health Agency and U.S. Coast Guard. The current order for Padcev, a specialty oncology medication, reflects the company's role as a critical vendor for specialized pharmaceutical commodities across multiple therapeutic domains within the Department of Defense supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.4k | 7/21/25 |